| Kevin Outterson |
use both this parameter and |birth_date to display the person's date of birth, date of death, and age at death) -->| death_place = | death_cause = | body_discovered = | resting_place = | resting_place_coordinates = | burial_place = | burial_coordinates = | monuments = | alma_mater = Northwestern UniversityUniversity of CambridgeUniversity of Reading| occupation = Law professor| years_active = | era = | employer = Boston University School of Law| organization = | agent = | known_for = Health Law, Intellectual Property Law, Antibiotic Resistance| notable_works = | style = | height = | television = | title = | term = | predecessor = | successor = | party = | movement = | opponents = | boards = | criminal_charges = | criminal_penalty = | criminal_status = | spouse = | partner = | children = | parents = | mother = | father = | relatives = | family = | callsign = | awards = | website = | module = | module2 = | module3 = | module4 = | module5 = | module6 = | signature = | signature_size = | signature_alt = | footnotes = }}Kevin Outterson is a lawyer, a professor of law and the Austin B. Fletcher Professor Boston University School of Law (2023-present).[1] He is also the executive director[2] of Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that supports companies[3] developing new antibiotics, diagnostics, vaccines and other products to address drug-resistant bacterial infections.
CARB-X is funded by[4] the United States, United Kingdom, German, and Canadian governments, Wellcome, the Bill & Melinda Gates Foundation, and the Novo Nordisk Foundation. In 2022, CARB-X received a new commitment of funding[5] from BARDA and Wellcome of up to $370 million. In 2023, the German and UK governments renewed funding to CARB-X, committing an additional €41 million and £24 million; the government of Canada committed CAD$6.3 million over two years; and The Novo Nordisk Foundation committed USD$25 million over three years.
The G7 Health Ministers have cited CARB-X[6] among the critical initiatives to support as the G7 governments renew their 2021 commitment to address the most dangerous drug-resistant infections. In May 2023, the global threat of Antimicrobial Resistance and the importance off supporting CARB-X as a global push incentive that coordinates and accelerates much-needed antibacterial innovation was featured in G7 Hiroshima Leaders’ Communiqué[7] and the G7 Nagasaki Health Ministers’ Communiqué.[8] The same year, G20 Health Ministers cited CARB-X as playing a critical role in accelerating antimicrobial R&D and access.[9] In May 2024, the Antimicrobial Resistance (AMR) Multi-Stakeholder Partnership Platform issued a call for actionable steps to address the rising threat of AMR ahead of the United Nations General Assembly High-Level Meeting on AMR in September 2024. The call recommended increasing public investment in push incentives to catalyze global antimicrobial R&D efforts and cited CARB-X as a push mechanism that should be mobilized due to CARB-X’s critical role in supporting the discovery and development or new antimicrobials.[10]
Outterson's research focuses primarily on the law and economics of antibiotic resistance–including push and pull incentives–health law, intellectual property, and global access to medicine.[11]
Outterson has testified before Congress, the World Health Organization (WHO), UK Parliamentary working groups, and for the District of Columbia, Massachusetts, Vermont, California and West Virginia state legislatures.[12]
He is co-director of the health law program at Boston University School of Law (2007–present) and associate fellow at the Royal Institute of International Affairs at Chatham House,[13] London (2014–present). He served on the Board of the American Society of Law, Medicine & Ethics, and serves as faculty editor to the American Journal of Law & Medicine (2007–present). He is past editor-in-chief of the Journal of Law, Medicine & Ethics (2010–2016).[11]